FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is a human antibody or an antigen-binding antibody fragment which specifically binds to human CD20 and contains CDR1-3 of a light chain and CDR1-3 of a heavy chain. What is described is a version of the antibody or antigen-binding antibody fragment characterised by amino acid sequences of the light and heavy chains. There are presented: a coding nucleic acid molecule, a based expression vector, as well as a method for producing the antibody or antigen-binding antibody fragment with using the vector. What is disclosed is a pharmaceutical composition based on the antibody. What is described is a method for reducing a severity or suppressing a CD20-caused disease or condition, and using the antibody or antigen-binding antibody fragment for preparing a medicine for reducing a severity or suppressing the CD20-mediated disease or condition.
EFFECT: invention provides the antibodies that extend asymptomatic survival from approximately 2 to approximately 9 times or more, relative to animals control in human lymphoma simulated in mice, have high affinity, that can be find application in medicine.
15 cl, 1 dwg, 14 tbl, 10 ex
